Skip to main content

Table 2 Predictors of WHOQoL-HIV BREF component 12 weeks after DAA treatment

From: Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus

  Level of independence Environment Spiritual/religion/personal beliefs Overall perception of QoL Overall perception of health
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate
RR, (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p
Male gender 2.56 (0.91–7.22) 0.050 4.01 (1.09–14.74) 0.037 0.86 (0.57–1.29) 0.677    1.12 (0.52–2.40) 0.992    1.49 (0.52–4.28) 0.559    1.36 (0.57–3.30) 0.654   
Age ≤ 40 year 1.02 (0.69–1.52) 1.000    1.09 (0.78–1.53) 0.735    1.50 (0.85–2.63) 0.203 1.88 (0.83–4.26) 0.130 0.84 (0.48–1.48) 0.702    0.93 (0.57–1.52) 0.918   
University education 0.84 (0.58–1.23) 0.462    0.96 (0.71–1.29) 0.901    0.84 (0.53–1.34) 0.581    0.71 (0.40–1.25) 0.306    1.07 (0.67–1.70) 0.911   
Married versus not married 1.50 (0.69–3.26) 0.407    0.83 (0.39–1.79) 0.334    1.06 (0.47–2.42) 0.496    0.97 (0.42–2.25) 0.604    1.05 (0.47–2.35) 0.529   
Married versus Widow/divorce 1.71 (0.65–4.50) 0.407    0.48 (0.18–1.29) 0.334    0.59 (0.23–1.53) 0.496    1.77 (0.54–5.77) 0.604    1.86 (0.62–5.53) 0.529   
Regular worker versus non-regular 0.57 (0.28–1.17) 0.127 0.62 (0.29–1.31) 0.215 1.25 (0.62–2.55) 0.735    1.13 (0.54–2.34) 0.933    1.46 (0.66–3.22) 0.383    1.90 (0.89–4.08) 0.249 1.99 (0.89–4.44) 0.094
Regular worker versus not working 1.45 (0.52–4.06) 0.127 0.77 (0.23–2.56) 0.663 0.90 (0.33–2.41) 0.735    0.96 (0.35–2.65) 0.933    2.14 (0.64–7.17) 0.383    1.45 (0.52–4.06) 0.249 1.20 (0.41–3.58) 0.738
CD4 > 500 versus 350–500 1.47 (0.57–3.82) 0.636    0.71 (0.28–1.81) 0.772    1.04 (0.39–2.79) 0.944    0.65 (0.24–1.80) 0.787    0.75 (0.28–1.99) 0.882   
CD4 > 500 versus < 350 0.79 (0.37–1.72) 0.636    0.77 (0.35–1.67) 0.772    0.82 (0.37–1.85) 0.944    0.71 (0.30–1.69) 0.787    0.79 (0.35–1.80) 0.882   
HCV-RNA > 800,000 IU/mL 1.02 (0.66–1.57) 1.000    1.04 (0.73–1.49) 0.992    0.87 (0.53–1.44) 0.749    0.55 (0.32–0.93) 0.054 0.42 (0.18–0.94) 0.035 0.67 (0.42–1.08) 0.177 0.59 (0.25–1.38) 0.225
Interferon failure 1.03 (0.56–1.91) 1.000    0.54 (0.24–1.24) 0.132 0.34 (0.10–1.15) 0.083 0.42 (0.12–1.54) 0.220 0.36 (0.07–1.80) 0.215 1.16 (0.49–2.75) 0.748    0.92 (0.39–2.16) 1,000   
Achieving SVR12 1.60 (0.49–5.23) 0.460    1.29 (0.54–3.06) 0.702    0.58 (0.29–1.16) 0.234 0.27 (0.05–1.45) 0.130 1.93 (0.31–12.07) 0.675    1.17 (0.35–3.85) 1,000   
Non-smoker 0.92 (0.64–1.33) 0.796    0.81 (0.60–1.09) 0.214 0.65 (0.33–1.26) 0.197 0.62 (0.39–0.99) 0.234 0.46 (0.23–0.95) 0.035 1.18 (0.69–2.03) 0.671    0.46 (0.28–0.77) 0.003 0.32 (0.15–0.66) 0.002
BMI normal versus underweight 0.71 (0.27–1.91) 0.001 0.75 (0.28–2.03) 0.572 0.63 (0.23–1.72) 0.554    0.70 (0.26–1.90) 0.685    0.60 (0.22–1.64) 0.108 0.56 (0.20–1.57) 0.274 0.70 (0.26–1.90) 0.778   
BMI normal versus overweight/obese 4.99 (1.88–13.19) 0.001 4.80 (1.79–12.81) 0.002 1.17 (0.53–2.57) 0.554    0.76 (0.33–1.72) 0.685    2.32 (0.81–6.65) 0.108 2.37 (0.81- 6.90 0.114 0.98 (0.42–2.27) 0.778   
Non-IVDU 0.67 (0.32–1.42) 0.373    0.91 (0.54–1.52) 0.908    0.70 (0.29–1.69) 0.571    0.92 (0.38–2.25) 1,000    0.94 (0.44–2.02) 1,000   
Fibrosis stage F0–F1 versus F2–F3 1.09 (0.47–2.51) 0.982    1.01 (0.44–2.34) 0.506    0.69 (0.29–1.62) 0.631    1.06 (0.40–2.83) 0.323    1.67 (0.64–4.35) 0.332   
Fibrosis stage F0–F1 versus F4 1.02 (0.44–2.38) 0.982    1.63 (0.70–3.80) 0.506    0.75 (0.31–1.80) 0.631    0.53 (0.22–1.30) 0.323    0.72 (0.30–1.71) 0.332   
Non-anemia 1.30 (0.74–2.26) 0.451    1.29 (0.81–2.06) 0.349    0.95 (0.53–1.69) 1.000    1.15 (0.54–2.44) 0.912    1.22 (0.62–2.40) 0.717   
NNRTI-based versus PI-based ART 1.07 (0.61–1.88) 0.993    1.34 (0.77–2.32) 0.360    3.62 (0.96–13.68) 0.036 5.23 (1.16–23.65) 0.032 1.81 (0.62–5.30) 0.371    2.26 (0.78–6.56) 0.145 3.26 (0.87–12.18) 0.078
  1. HCV-RNA: hepatitis C virus ribonucleic acid; SVR12: sustained virological response at 12 weeks post treatment; BMI: body mass index; IVDU: intravenous drug user; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; ART: antiretroviral therapy